Article
Author(s):
ICYMI, this week we had stories on the latest coverage from the 2022 American Academy of Dermatology Annual meeting, coverage from the 18th Annual Skin of Color Symposium, and more.
This week's edition of the Mainstream Patients features stories about scalp acne, how to avoid skin irritation with a fitness tracker, and more.
Implementation challenges and loopholes limit laws’ impact.
More hikes expected to help slow rising inflation.
Physicians’ group cites CDC data in letter to lawmakers.
Physicians have a role in stamping out weight bias.
Cancer programs seek to remove barriers to screenings.
In this video the OJM group talks about volatile markets and how to navigate investing in uncertain times.
Laser hair removal was the most litigated.
A recent study aimed to identify whether using specific serum biomarkers could predict therapeutic response in patients with atopic dermatitis.
Experts share insight on the challenges inherent in treating patients with atopic dermatitis despite recent advances in therapy.
The 3rd Annual San Diego Dermatology Symposium (SDDS) was held in-person for the first time on March 11 to 13, 2022, at the Hilton San Diego Bayfront, in California.
Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.
Data from the RELIEVE-AD study show long-term control and treatment satisfaction.
Vial Dermatology CRO announced that the associate professor of dermatology and rheumatology at Harvard Medical School and the vice chair of clinical trials and innovation at Brigham and Women's Hospital in Boston, Massachusetts, has joined its Scientific Advisory Board.
Today, the 18th Annual Skin of Color Scientific Symposium begins, showcasing new research in the field, key insights, and the evolution in skin of color dermatology.
Benjamin Lockshin, MD, FAAD, comments on the significance of recent expansions of therapeutics options for patients with atopic dermatitis and unmet needs in the field.
Benjamin Lockshin, MD, FAAD, reviews key findings from a phase 2 trial evaluating the safety and efficacy of single-dose dupilumab in children with severe atopic dermatitis.
An expert dermatologist evaluates the role of dupilumab in decreasing the clinical burden of severe atopic dermatitis on patients and their caregivers and shares insight on the future outlook of dupilumab in disease management.
In this week’s Pointers with Dr Portela, the 208SkinDoc discusses how treatments are often too expensive for patients, which causes them to be labeled as “non-compliant.” He discusses ways to improve adherence for both patients and doctors
The American Academy of Dermatology Annual meeting starts today, offering presentations focusing on the latest treatment updates, new data, plus much more.
Investigator Loren Krueger, MD, urges dermatologists to recognize and correct disparities in clinical decision-making, particularly regarding skin cancer.
Mariam Totonchy, MD, and Chrysalyne D. Schmults, MD, MSCE, discuss best practices when caring for high-risk cSCC patients, including surgical vs nonsurgical options, imaging, and follow-up protocol.
In a presentation at the current AAD annual meeting, experts discussed differential diagnoses and clinical presentations in birthmarks and hamartomas.
In this video interview, we sit down with Natasha Atanaskova Mesinkovska, MD, PhD, FAAD, to discuss her 2022 AAD annual meeting presentation on alopecia areata. We dive into pipeline possibilities, what current treatments are missing, and more.